MindWalk Holdings Corp. (HYFT)
| Market Cap | 96.65M |
| Revenue (ttm) | 19.02M |
| Net Income (ttm) | -21.29M |
| Shares Out | 46.69M |
| EPS (ttm) | -0.50 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 654,621 |
| Open | 1.980 |
| Previous Close | 2.000 |
| Day's Range | 1.820 - 2.200 |
| 52-Week Range | 0.270 - 3.246 |
| Beta | 0.48 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Dec 15, 2025 |
About HYFT
MindWalk Holdings Corp. operates as a bio-native AI company. It focuses on the integration of artificial intelligence, multi-omics data, and advanced laboratory research to accelerate the discovery and development of biologics. The company, through its LensAI platform and HYFT technology, it partners with pharmaceutical and biotechnology companies to drive de-risk drug development and unlock therapeutic possibilities. The company was formerly known as ImmunoPrecise Antibodies Ltd. and changed its name to MindWalk Holdings Corp. in September 202... [Read more]
Financial Performance
In 2025, MindWalk Holdings's revenue was 24.52 million, an increase of 0.01% compared to the previous year's 24.52 million. Losses were -30.23 million, 15.8% more than in 2024.
Financial numbers in CAD Financial StatementsNews
MindWalk Validates Platform Precision with Breakthrough Discovery Targeting Pathogenic TDP-43 in Neurodegenerative Disease
VICTORIA, British Columbia--(BUSINESS WIRE)--MindWalk Holdings Corp. (“MindWalk” or the “Company”) (Nasdaq: HYFT) today announced the discovery and validation of monoclonal antibodies and intrabodies ...
REPEAT/MindWalk Advances Universal Influenza Program with a Breakthrough Functional Insight
AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. (NASDAQ:HYFT) (“MindWalk” or the “Company”), a Bio-Native AI therapeutic research and technology company, today announced an advance in its univ...
MindWalk Advances Universal Influenza Program with a Breakthrough Functional Insight
AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. (NASDAQ:HYFT) (“MindWalk” or the “Company”), a Bio-Native AI therapeutic research and technology company, today announced an advance in its univ...
MindWalk Holdings Corp. (HYFT) Q2 2026 Earnings Call Transcript
MindWalk Holdings Corp. (HYFT) Q2 2026 Earnings Call Transcript
MindWalk Reports Record Growth and Announces Strategic Progress on Its AI Asset Pipeline
VICTORIA, British Columbia--(BUSINESS WIRE)---- $HYFT #ai--MindWalk (NASDAQ: HYFT), a BioNative AI biotherapeutic research and technology company combining in silico and wet lab operations for biologi...
MindWalk Holdings Corp. to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2026 on December 15, 2025
AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. (NASDAQ:HYFT) (“MindWalk” or the “Company”), a Bio-Native AI therapeutic research and technology company, today announced that it will host a co...
MindWalk CTO Dr. Dirk Van Hyfte to Join Fireside Chat at AI Drug Discovery & Development Summit 2025
AUSTIN, Texas--(BUSINESS WIRE)---- $HYFT #AI--MindWalk Holdings Corp.™ (“MindWalk,” “Company,” “we” or “us”) (Nasdaq: HYFT), a Bio-Native AI company, today announced that Dr. Dirk Van Hyfte, Chief Tec...
MindWalk Appoints R. Scott Areglado as Chief Financial Officer to Strengthen Financial Leadership and Support Growth Strategy
AUSTIN, Texas--(BUSINESS WIRE)---- $HYFT #AI--MindWalk Holdings Corp.™ (“MindWalk,” “Company,” “we” or “us”) (Nasdaq: HYFT), bio-native AI company today announces the appointment of industry veteran R...
MindWalk Holdings: Repositioned TechBio Platform With Early LensAI Proof Points
MindWalk Holdings (HYFT) has pivoted to an asset-light, AI-driven techbio platform, leveraging its HYFT and LensAI technologies for in silico drug discovery. LensAI's early successes include a dual-ac...
MindWalk Appoints Dr. Thomas W. Lynch as Chief Business Officer to Accelerate Commercial Expansion
AUSTIN, Texas--(BUSINESS WIRE)---- $HYFT #AI--MindWalk Holdings Corp.™ (“MindWalk,” “Company,” “we” or “us”) (Nasdaq: HYFT), a Bio-Native AI company today announced the appointment of industry veteran...
MindWalk Holdings Corp. (HYFT) ImmunoPrecise Antibodies Ltd. - Shareholder/Analyst Call Prepared Remarks Transcript
MindWalk Holdings Corp. (NASDAQ:HYFT) ImmunoPrecise Antibodies Ltd. - Shareholder/Analyst Call October 9, 2025 1:00 PM EDT Company Participants Jennifer Bath - CEO, President & Non-Independent Direct...
MindWalk Announces Share Repurchase Program
AUSTIN, Texas--(BUSINESS WIRE)---- $hyft #AI--MindWalk Holdings Corp. (“MindWalk” or the “Company”) (NASDAQ: “HYFT”), a bio-native AI company, today announced that to underscore its confidence in Mind...
MindWalk Advances AI-Designed GLP-1 Program with First-in-Class Dual-Pathway Regimen for Aging and Longevity
AUSTIN, Texas--(BUSINESS WIRE)---- $HYFT #AI--MindWalk Holdings Corp.™ (“MindWalk,” “Company,” “we” or “us”) (Nasdaq: HYFT), a Bio-Native AI company, today announced a major advancement of its AI-desi...
MindWalk Holdings Corp. (HYFT) Q1 2026 Earnings Call Transcript
MindWalk Holdings Corp. (NASDAQ:HYFT) Q1 2026 Earnings Call September 15, 2025 10:30 AM EDT Company Participants Jennifer Bath - CEO, President & Non-Independent Director Joseph Scheffler - Interim C...
MindWalk Holdings Corp.™ (formerly ImmunoPrecise Antibodies™) Reports Record $7.6 Million Quarterly Revenue, 45% Growth, Margin Expansion, Narrowed Losses, and Strengthened Balance Sheet
AUSTIN, Texas--(BUSINESS WIRE)---- $HYFT #AI--MindWalk Holdings Corp.™ (“MindWalk™”, “Company”, “we” or “us”) (NASDAQ: HYFT), a Bio-Native AI company operating at the intersection of TechBio and next-...
ImmunoPrecise Rebrands as MindWalk, Announces NASDAQ Ticker Change to “HYFT”
AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), ImmunoPrecise Antibodies Ltd. and its subsidiaries (BioStrand and Talem) today announ...
ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 27th Annual Global Investment Conference in New York
AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), today announced that it will participate in the 27th Annual H.C. Wainwright Global In...
ImmunoPrecise Advances AI Discovered and Developed Universal Dengue Vaccine Initiative: Moves into Preclinical Antibody Generation
AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a biotherapeutics company delivering advanced solutions in biologics and drug discove...
ImmunoPrecise Antibodies Ltd. Divests Netherlands Facilities to AVS Bio to Accelerate Bio-Native AI Innovation
AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a biotherapeutics company delivering advanced solutions in biologics and drug discove...
AVS Bio, an Arlington Capital Partners Portfolio Company, Expands Antibody Discovery and Protein Production Capabilities With Acquisition of ImmunoPrecise Antibodies Europe From ImmunoPrecise Antibodies Ltd.
WASHINGTON & NORWICH, Conn.--(BUSINESS WIRE)--Arlington Capital Partners (“Arlington”), a Washington, D.C.-area private investment firm specializing in government regulated industries, today announced...
ImmunoPrecise Antibodies Ltd. (IPA) Q4 2025 Earnings Conference Call Transcript
ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Q4 2025 Earnings Call July 29, 2025 10:30 AM ET Company Participants Jennifer Lynne Bath - CEO, President & Non-Independent Director Joseph Scheffler - Inte...
ImmunoPrecise Antibodies (IPA) Reports Full Fiscal Year 2025 Results, Record Fourth Quarter Revenue, and Record Fourth Quarter Adjusted EBITDA
AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (“IPA”, “Company”, “we” or “us”) (NASDAQ: IPA), a bio-native AI company operating at the intersection of TechBio and next-gen...
ImmunoPrecise Releases New Findings Showing LENSai™ Quickly Flags Anti-Drug-Antibody Risk—Long Before the Clinic
AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a Bio-Native AI pioneer operating where TechBio meets true biological intelligence, t...
ImmunoPrecise Appoints Healthcare Data Visionary Jeff Fried to Advisory Board
AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a bio-native AI company operating at the intersection of TechBio and next-generation ...
IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2025 on July 29, 2025
AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a bio-native AI company operating at the intersection of TechBio and next-generation ...